Bladder Mass and Hematuria Found in 53-Year-Old Man

Poll

A 53-year-old man presents with hematuria and is found to have a bladder mass. What is your diagnosis?

A 53-year-old man presents with hematuria and is found to have a bladder mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Mucocele of the bladder
B. Inverted papilloma
C. Transitional cell carcinoma
D. Mucinous signet-ring cell adenocarcinoma
Recent Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content
The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

Roman Fabbricatore
August 29th 2024
Article

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.

Lenvatinib Combo Improves Clinical Benefit in Clear Cell RCC Subgroups

Megan Hollasch
June 4th 2024
Article

Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas

Matthew Fowler;Quirin Zangl, MD
November 22nd 2021
Podcast

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.

Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell Carcinoma

Ben Saylor
June 4th 2024
Article

Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.

Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.

Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC

Jonah Feldman
June 4th 2024
Article

Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.